
Hemophilia Societies: Challenges and Development
Outlines the common challenges faced by hemophilia societies at various stages of development and offers practical solutions to help these
Year: 2021
Language: English
Author(s): World Federation of Hemophilia
Format: Video
In this session from the Global Policy and Access Summit, Dawn Rotellini, Mark Skinner, Jamie O’Hara and David Page will present an overview of the current state of access to therapies for people with bleeding disorders. Speakers will also highlight the importance of patient-relevant data on treatment choices and health policy decision-making. Session will include a case study and concrete recommendations will be brought forward for patient organizations to advocate for increased access to therapies.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Outlines the common challenges faced by hemophilia societies at various stages of development and offers practical solutions to help these

This guide helps national hemophilia organizations plan and carry out an outreach campaign to identify people with hemophilia or other

Also Available In: Japanese A national tender is a cost-effective system for the purchase of products or services, such as

Also Available In: Japanese Patient registries are crucial for monitoring trends in health, allocating resources, organizing and tracking distribution of

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 患者登録は、健康上の傾向のモニタリング、資源の割り当て、治療用製剤供給の調整および追跡、全国規模での購入プロセスの改善に極めて重要です。

Having a national patient registry means being able to answer fundamental questions about the hemophilia population within a given country.